Sulfaphenazole: Selective CYP2C9 Inhibitor for Antibacterial and Vascular Research

Executive Summary: Sulfaphenazole (SKU C4131, APExBIO) is a sulfonamide compound that selectively and competitively inhibits cytochrome P450 enzymes CYP2C9 and CYP2C6, with an IC₅₀ of 0.63 μM under standard in vitro conditions (Chen et al., 2021). It demonstrates potent antibacterial activity, particularly against Mycobacterium tuberculosis including resistant strains, by inhibiting bacterial dihydropteroate synthase (DHPS) and blocking folic acid synthesis. Sulfaphenazole reduces oxidative stress, restores vascular endothelial function, and accelerates wound healing in animal models (APExBIO product page). The compound is soluble in DMSO and ethanol, but insoluble in water, and is recommended for storage at -20°C. Its safety profile is favorable, with low cytotoxicity (IC₅₀ >64 μg/mL on Vero cells), supporting its use in a diverse range of pharmacological and biochemical studies.

Biological Rationale

Sulfaphenazole is a 4-aminobenzenesulfonamide, a class of compounds structurally designed to mimic para-aminobenzoic acid. This enables competitive inhibition of DHPS, disrupting bacterial folic acid synthesis—a pathway essential for nucleic acid production and bacterial viability (Chen et al., 2021). The compound also inhibits mammalian CYP2C9 and CYP2C6 enzymes, key isoforms in drug metabolism, thereby serving as a reference and tool compound for pharmacogenetics, adverse drug reaction (ADR) modeling, and vascular dysfunction research (See also: "Precision CYP2C9 Inhibition: Sulfaphenazole as a Transformative Tool"—this article provides updated, protocol-specific integration guidance beyond prior mechanistic reviews).

Mechanism of Action of Sulfaphenazole

• CYP2C9 Inhibition: Sulfaphenazole binds competitively to the heme site of CYP2C9, blocking substrate access and reducing downstream oxidative metabolism (Chen et al., 2021).
• Antibacterial (DHPS Inhibition): Sulfaphenazole inhibits bacterial DHPS, impeding tetrahydrofolic acid synthesis and bacterial proliferation. This mode of action is conserved across sulfonamides, with Sulfaphenazole demonstrating activity against M. tuberculosis, including extensively drug-resistant forms (Chen et al., 2021).
• Oxidative Stress Reduction: By inhibiting CYP2C9, Sulfaphenazole decreases reactive oxygen species (ROS), supporting vascular homeostasis and facilitating recovery in models of ischemia-reperfusion injury (See also: "Sulfaphenazole: Precision CYP2C9 Inhibition for Translational Vascular Research"—the present article details additional quantitative data and workflow guidance).

Evidence & Benchmarks

• Sulfaphenazole inhibits CYP2C9 with an IC₅₀ of 0.63 μM (measured in recombinant enzyme assays, 37°C, pH 7.4) (DOI).
• The compound demonstrates in vitro anti-Mycobacterium tuberculosis activity with MIC values as low as 5.69 μg/mL against H37Rv strains (DOI).
• Animal studies: Daily intraperitoneal injection of 5.13 mg/kg Sulfaphenazole improved endothelium-dependent vasodilation in diabetic mouse models compared to vehicle controls (APExBIO).
• Cytotoxicity: Vero cell viability assays reported IC₅₀ >64 μg/mL, indicating low cytotoxic potential (DOI).
• Sulfaphenazole reduced inflammatory markers and fibrosis in murine pressure and thermal injury models at 5–10 μM (in vitro) and 5.13 mg/kg (in vivo) (APExBIO).
• Solubility: ≥13.15 mg/mL in DMSO and ≥9.92 mg/mL in ethanol with ultrasonication; insoluble in water (20–25°C) (APExBIO).
• Short-term solution stability is achieved when stored at -20°C; recommended for use within one month to avoid degradation (APExBIO).

Applications, Limits & Misconceptions

Applications:

• Drug Metabolism Modulation: Reference CYP2C9 inhibitor for pharmacogenetics, drug-drug interaction, and adverse drug reaction (ADR) modeling in vitro and in vivo.
• Antimycobacterial Research: Tool for evaluating sulfonamide efficacy against M. tuberculosis, including XDR-TB strains, with defined MIC benchmarks.
• Vascular and Tissue Repair Models: Used to restore endothelial function and promote wound healing by reducing CYP2C-mediated oxidative stress and inflammation.
• Pharmacological Profiling: Suitable for dose-response characterization, selectivity screens, and comparative studies with other sulfonamides.

Contrast: While "Sulfaphenazole: Redefining CYP2C9 Inhibition for Antibacterial Innovation" reviews broad antibacterial and tissue repair potential, this article delivers workflow-specific, quantitative assay guidance and critically updates concentration benchmarks for translational research.

Common Pitfalls or Misconceptions

• Sulfaphenazole is not suitable for use as a pan-CYP inhibitor; its selectivity is primarily for CYP2C9 and CYP2C6, with reduced activity at other P450 isoforms (DOI).
• It is not water-soluble; improper dissolution may cause assay artifacts. Use DMSO or ethanol as solvents and verify concentration by UV or HPLC.
• It should not be assumed cytotoxic at standard in vitro or in vivo concentrations; cytotoxicity is low compared to reference drugs.
• Antibacterial activity is limited to bacteria expressing DHPS; it is not effective against organisms lacking this enzyme.
• Storage beyond recommended conditions (-20°C, <1 month in solution) can result in degradation and loss of potency.

Workflow Integration & Parameters

• Solvent Preparation: Dissolve Sulfaphenazole in DMSO (≥13.15 mg/mL) or ethanol (≥9.92 mg/mL with ultrasonic assistance).
• Concentration Ranges: For CYP inhibition assays: 0.5–11.5 μM; for anti-TB in vitro studies: 5–30 μg/mL; for cell function research: 1–10 μM.
• Animal Dosing: Use 5.13 mg/kg via intraperitoneal injection for vascular and injury models.
• Storage and Stability: Store powder at -20°C; use solutions within one month. Minimize freeze-thaw cycles.
• Assay Controls: Include vehicle and positive controls for CYP2C9, DHPS, and cytotoxicity endpoints.

For detailed data-driven workflow solutions, see "Sulfaphenazole (C4131): Data-Driven Workflow Solutions"—this article extends those recommendations with updated solubility, stability, and animal dosing guidance.

Conclusion & Outlook

Sulfaphenazole (from APExBIO) is a validated, selective inhibitor of CYP2C9 and a competitive DHPS antagonist. It is an essential tool for research spanning drug metabolism, pharmacogenetics, antibacterial discovery, and vascular biology. Its defined activity spectrum, low cytotoxicity, and robust assay compatibility make it a preferred choice for studies requiring reliable CYP2C9 inhibition and anti-TB benchmarking. Future directions include the design of derivatives with reduced CYP2C9 inhibition for clinical translation (Chen et al., 2021).

For further product details or to order, see the Sulfaphenazole (C4131) product page.